Hims & Hers (HIMS) Stock Drops 7% After Q2 Loss Overshadows Revenue Guidance Hike

TLDR

• Hims & Hers raised full-year revenue guidance to $3.1B-$3.3B, beating Wall Street’s $2.93B estimate
• Q2 revenue came in at $753.2M, topping estimates, but the company swung to a loss of $0.37 per share vs. a 5-cent loss expected
• HIMS stock fell nearly 7% in premarket Tuesday after dropping 5.5% in after-hours Monday
• Gross margins fell for the fourth straight quarter as costs surged, with total operating costs up 48% year-over-year
• The company faces ongoing restructuring charges as it exits compounded GLP-1 drugs and shifts toward branded weight-loss products

Hims & Hers Health raised its 2026 revenue guidance well above Wall Street expectations on Monday, but investors weren’t buying it. The stock dropped 5.5% in after-hours trading and fell nearly 7% in premarket Tuesday.

Hims & Hers Health, Inc., HIMS

The telehealth company now expects full-year revenue between $3.1 billion and $3.3 billion, up from its prior range of $2.8 billion to $3 billion. Q3 guidance of $880 million to $900 million also cleared analyst estimates of $792.2 million.

… Continue reading the full article at the original source below.